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ConCise report
The efficacy of motivational counselling and SMS 
reminders on daily sitting time in patients with 
rheumatoid arthritis: a randomised controlled trial
tanja thomsen,1 Mette Aadahl,2,3 nina Beyer,4,5 Merete Lund Hetland,1,5,6 
Katrine Løppenthin,1 Julie Midtgaard,3,7 robin Christensen,8 Mikkel Østergaard,1,5 
poul Jørgen Jennum,5,9 Bente Appel esbensen1,5
AbstrACt
Objectives the aim of this report is to investigate 
the efficacy of an individually tailored, theory-based 
behavioural intervention for reducing daily sitting time, 
pain and fatigue, as well as improving health-related 
quality of life, general self-efficacy, physical function and 
cardiometabolic biomarkers in patients with rheumatoid 
arthritis (rA).
Methods in this randomised controlled trial 150 
patients with rA were randomised to an intervention 
or a no-intervention control group. the intervention 
group received three individual motivational counselling 
sessions and short message service or text messages 
aimed at reduction of sedentary behaviour during the 
16-week intervention period. primary outcome was 
change in daily sitting time measured objectively by 
ActivpAL. secondary outcomes included change in pain, 
fatigue, physical function, general self-efficacy, quality 
of life, blood pressure, blood lipids, haemoglobin A1c, 
body weight, body mass index, waist circumference and 
waist–hip ratio.
results 75 patients were allocated to each group. 
Mean reduction in daily sitting time was −1.61 hours/
day in the intervention versus 0.59 hours/day increase in 
the control group between-group difference −2.20 (95% 
Ci −2.72 to −1.69; p<0.0001) hours/day in favour of 
the intervention group. Most of the secondary outcomes 
were also in favour of the intervention.
Conclusion An individually tailored, behavioural 
intervention reduced daily sitting time in patients with 
rA and improved patient-reported outcomes and 
cholesterol levels.
trial registration number nCt01969604; results.
IntrOduCtIOn
Rheumatoid arthritis (RA) causes disability1 and 
barriers for exercise.2 Patients with RA have a 
50%–60% increased risk of premature death from 
cardiovascular disease.3 Supplementary to the phar-
macological treatment, patients are recommended 
to engage in moderate-to-high intensity aerobic and 
resistance training.4 5 Most patients do not meet 
recommended levels of moderate-to-vigorous phys-
ical activity6 and 71%–92% of waking hours are 
spent sedentarily.7 Sedentary behaviour is defined 
as sitting or reclining while awake and with low-en-
ergy expenditure.8 In patients with chronic disease 
and mobility limitations, replacing sedentary 
behaviour with light intensity activities may prove 
more achievable than solely focusing on increasing 
moderate-to-vigorous physical activity.9 10 Studies 
have shown that reduction of daily sitting time 
through intervention is possible.11 12 Also, 
improved resting blood pressure, insulin levels 
and plasma glucose following regular interrup-
tions of prolonged sitting have been reported.13 We 
aimed to investigate the efficacy of an individually 
tailored, theory-based behavioural intervention for 
reducing daily sitting time, pain and fatigue, as well 
as improving quality of life, general self-efficacy, 
physical function and cardiometabolic biomarkers 
in patients with RA.
MethOds
We performed an observer-blinded randomised 
controlled trial. The protocol was reported to 
the Danish Data Protection Agency (711-1-08), 
approved by the Ethics Committee of the Capital 
Region of Denmark (H-2-2012-112) and regis-
tered at www. clinicaltrials. gov (NCT01969604). 
The Danish National Board of Health Biological 
Therapies (DANBIO) database14 was searched for 
potential participants. A detailed description of the 
methods of the trial has previously been published. 
See protocol and feasibility paper.15 16
Patients were randomised 1:1 to intervention 
(n=75) or control group (n=75) by computer 
generated random numbers in blocks of 10. Partic-
ipants and project staff delivering the intervention 
were unblinded to the participants’ allocation status, 
whereas outcome assessors and the statistician were 
blinded to allocation. The 16-week individually 
tailored, behavioural intervention consisted of three 
motivational counselling sessions conducted by 
health professionals and individual short message 
service (SMS) or text messages aiming to increase 
light intensity physical activity through reduction 
of sedentary behaviour. Participants randomised to 
the control group were instructed to maintain their 
usual lifestyles.
The primary outcome measure was change 
in daily sitting time measured by an ActivPAL 
3TM V.7.2.32 Activity Monitor (PAL Technolo-
gies, Glasgow, UK). The ActivPAL uses accelerom-
eter-derived information to determine time spent 
sitting/lying, standing and stepping and is validated 
in patients with RA.17 The participants wore the 
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monitor 24 hours per day for 7 days at baseline and by end of 
intervention, and recorded their daily sleeping time to separate 
sleep from waking sitting/lying time.
Secondary outcomes were changes from baseline to 16 weeks 
in self-reported daily sitting time at work and during leisure 
time and number of interruptions (‘breaks’) in daily sitting time, 
pain, fatigue physical function, quality of life (QoL) and general 
self-efficacy.15 Height was measured at baseline. Body weight, 
hip and waist circumference were additionally measured after 
16-week intervention and body mass index (BMI, kg/m2) and 
waist–hip ratio were calculated. Venous blood sample were 
drawn. Total cholesterol, high-density lipoprotein cholesterol, 
low-density lipoprotein cholesterol, triglycerides, haemo-
globin A1c and resting blood pressure were measured. Pharma-
cological treatment, duration of RA, C reactive protein, disease 
activity (Disease Activity Score 28), IgM rheumatoid factor and 
anti-cyclic citrullinated peptide (CCP) status were retrieved 
from DANBIO. Additional characteristics were obtained from a 
self-report questionnaire.15
Data analyses were based on the intention-to-treat population 
and carried out using SAS V.9.3 (SAS Institute) according to the 
protocol.15 Missing data were replaced with the value at base-
line carried forward. All reported p values and 95% CIs were 
two sided. Unless stated otherwise, results are expressed as the 
difference between the group (least-squares) means and 95% CI, 
based on a general linear model: data were analysed using anal-
ysis of covariance with a factor for group and baseline values 
as covariates in the model. For dichotomous outcomes, propor-
tions were compared based on the risk difference with 95% CIs, 
as well as including a Wald z test.
The trial was powered for a comparison between the partici-
pants allocated to intervention and control group, assuming that 
the intervention group condition would produce a reduction in 
daily sitting time of 50 min. Enrolling 75 patients in each group 
had a reasonable power (84.7%) to detect a mean difference 
of 50 min.15 16 A patient with RA from the Danish Rheumatism 
Association was involved in designing of the trial, including 
intervention and patient information.18
results
Participants
One thousand and eight patients were screened via DANBIO, 
hereof 801 (79%) were invited. Telephone-based screening was 
conducted with 722 of these, hereof 617 (85%) were eligible. Of 
these, 467 declined to participate (online supplementary figure 
S1). Compared with those declining participation, the included 
patients were older (60 vs 52 years), had longer disease duration 
(15 vs 12 years), lower Health Assessment Questionnaire (HAQ) 
(0.7 vs 1.1) and more were women (81% vs 69%). Outcomes 
were obtained for 147 (98%) of the randomised patients.
The intervention group had higher scores on fatigue, pain, 
had more daily sitting time and self-reported leisure-time sitting 
than the control group (9.8 vs 8.8 hours and 5.3 vs 4.3 hours, 
respectively) (online supplementary table S1). All in the inter-
vention group completed the counselling sessions (30–90 min) 
and had SMS reminders.
Primary outcome
Reductions in daily sitting time favoured the intervention group 
(online supplementary figure S2). Estimates of intervention effect 
for behavioural and patient-reported outcomes are presented 
in table 1. Objectively measured daily sitting time decreased in 
intervention group by on average 1.61 hours/day and increased 
in control group by 0.59 hours/day. The difference in change 
between groups was statistically significant in favour of inter-
vention group (−2.20 hours/day (95% CI −2.72 to −1.69)). The 
decrease in daily sitting time was replaced by increased standing 
table 1 Mean changes in behavioural and patient-reported outcomes after 16 weeks
Variable
Mean change from baseline mean (95% CI) difference in change between 
groups mean (95% CI) p ValueIntervention group Control group
Daily sitting time (ActivPAL) hours/day −1.61 (−1.97 to −1.25) 0.59 (0.24 to 0.95) −2.20 (−2.72 to −1.69) <0.0001
Daily standing time* (ActivPAL) hours/day 1.25 (0.82 to 1.68) −0.27 (−0.45 to 0.78) 1.52 (1.10 to 1.95) <0.001
Daily stepping time* (ActivPAL) hours/day 0.50 (0.26 to 0.95) −0.05 (−0.32 to 0.64) 0.55 (0.35 to 0.74) <0.001
Breaks up of daily sitting (ActivPAL) (number/day) −0.47 (−3.52 to 2.57) −1.97 (−5.02 to 1.07) 1.50 (−2.81 to 5.81) 0.49
Self-reported sitting time at work (hour/day) −1.12 (−1.68 to −0.57) 0.005 (0.54 to 0.55) −1.13 (−1.90 to −0.35) 0.005
Self-reported sitting time in leisure (hour/day) −1.30 (−1.68 to −0.93) 0.15 (−0.22 to 0.53) −1.46 (−2.00 to −0.92) <0.0001
Physical function (HAQ) −0.28 (−0.36 to −0.19) 0.14 (0.06 to 0.22) −0.42 (−0.54 to −0.30) <0.0001
Fatigue (VAS)/mm −19.04 (−24.22 to −13.86) 7.77 (2.59 to 12.95) −26.80 (−34.32 to −19.30) <0.0001
Fatigue (MFI)
  General fatigue −2.17 (−3.00 to −1.35) 1.25 (0.44 to 2.07) −3.43 (−4.59 to −2.26) <0.0001
  Physical fatigue −3.18 (−4.02 to −2.34) 1.34 (0.50 to 2.18) −4.52 (−5.73 to −3.30) <0.0001
  Mental fatigue −1.80 (−2.50 to −1.10) 0.65 (−0.05 to 1.35) −2.46 (−3.46 to −1.46) <0.0001
  Reduced activity −3.28 (−4.05 to −2.50) 1.60 (0.83 to 2.37) −4.88 (−5.99 to −3.77) <0.0001
  Reduced motivation −1.35 (−2.00 to −0.69) 1.26 (0.60 to 1.91) −2.60 (−3.54 to −1.67) <0.0001
Pain (VAS)/mm −14.77 (−19.50 to −10.04) 7.59 (2.58 to 12.32) −22.36 (−29.27 to −15.44) <0.0001
Self-efficacy (GSES) 3.96 (2.80 to 5.12) −2.25 (−3.41 to −1.09) 6.21 (4.54 to 7.88) <0.0001
HR-QoL (SF-36)
  SF36-PCS 6.30 (4.33 to 8.26) −2.58 (−4.54 to −0.61) 8.88 (6.06 to 11.69) <0.0001
  SF36-MCS 4.94 (3.42 to 6.46) −1.83 (−3.34 to −0.32) 6.77 (4.62 to 8.92) <0.0001
*Not an outcome measure, however, changes in daily sitting, standing and/or stepping time are interdependent, and reduced sitting time may be replaced by either standing or 
stepping time.
GSES, General Self-efficacy Scale; HAQ, Health Assessment Questionnaire; HR-QoL, Health-Related Quality of Life; MCS, Mental Component Scale; MFI, Multidimensional Fatigue 
Inventory; PCS, Physical Component Scale; SF36, 36-Item Short Form Survey Instrument; VAS, Visual Analogue Scale.
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and stepping time with between-group differences in change of 
1.52 hours/day and 0.55 hours/day, respectively.
secondary outcomes
Statistically significant differences in favour of the intervention 
group were found in self-reported daily sitting time at work and 
during leisure time, for fatigue, pain, physical function, QoL, 
general self-efficacy and in total cholesterol (tables 1 and 2); also 
significantly greater proportions achieved clinically meaningful 
improvements in physical function (HAQ) (minimal clinically 
important difference (MCID)=0.22), fatigue (Visual Analogue 
Scale) (MCID=10 mm) and pain (MCID=10 mm) (table 2).19
For anthropometric and cardiometabolic measures, no statis-
tically significant differences were found, but numerical differ-
ences in change were all in favour of intervention group (table 3).
dIsCussIOn
Individual motivational counselling sessions during a 16-week 
period accompanied by individual SMS reminders reduced daily 
sitting time by more than 2 hours compared with the control 
group. Patient-reported outcomes also improved and, to a lesser 
extent, cardiometabolic biomarkers. Patients with RA need to 
manage consequences of an unpredictable disease every day, 
why the intervention was individualised and targeted seden-
tary behaviour. This whole-day approach was also targeted in a 
similar individually tailored, behavioural intervention aiming to 
reduce daily sitting time in healthy adults.12 That study showed 
a non-significant between-group difference in daily sitting time 
of −0.32 hours, but a statistically significant difference in waist 
circumference and fasting insulin levels in favour of the interven-
tion group after 6-month intervention. Our 16-week interven-
tion period may not be long enough to detect significant changes 
in other cardiometabolic biomarkers than total cholesterol. 
Additionally, the changes in waist circumference almost reached 
statistical significance, which supports the call for a longer inter-
vention period.
The magnitude of changes in physical function, fatigue and 
pain was also assessed by looking at a clinical impact of the inter-
vention on RA-related outcomes. Achievement of the MCID was 
consistently reached for greater proportions in the intervention 
group. Without neglecting the important and well-established 
health benefits of engaging in moderate-to-vigorous physical 
activity, our results indicate that patients with RA can achieve 
substantial health benefits by reducing sitting time. This would 
have implications for clinical practice and physical activity 
recommendations.
Strengths include the randomised controlled design, blinding 
of outcome assessors and objective measurements. The two 
groups differed in their baseline measures with respect to daily 
sitting time, pain and fatigue. However, we regard these differ-
ences as random occurrences.
We cannot rule out that the significant changes in cholesterol 
levels and self-reported clinical outcomes were reached by other 
pathways than through increases in low-intensity, non-exercise 
physical activity, for example, through healthy dietary habits.
The results may not be generalisable to all patients with RA, 
since those how declined participation were younger and the 
proportion of men was higher. The intervention may have been 
more appealing to women, since 81% of the included patients 
were women; however, up to 75% of patients with RA are 
women.20 It is also noteworthy that participants were older and 
had longer disease duration than non-participants. Focus on 
light everyday activities and individual tailoring may be partic-
ular appealing to this group of patients. Only three participants 
table 2 Proportions of participants achieving clinically important improvements in physical function, fatigue and pain with corresponding risk 
differences
Variable
number (%)
risk difference (95% CI) p ValueIntervention group Control group
Achieved 0.22 improvement in HAQ scores 38 (51) 4 (5) 46% (33% to 58%) 0.0001
Achieved 10 mm improvement on VAS for fatigue 46 (62) 10 (14) 48% (35% to 62%) 0.0001
Achieved 10 mm improvement on VAS for pain 47 (64) 9 (12) 51% (38% to 64%) 0.0001
HAQ, Health Assessment Questionnaire; VAS, Visual Analogue Scale.
table 3 Mean changes in anthropometric and cardiometabolic biomarkers after 16 weeks
Variable
Mean change from baseline, mean (95% CI) difference in change between groups, 
mean (95% CI) p ValueIntervention group Control group
Weight (kg) 0.00 (−0.91 to 0.92) 0.58 (−0.34 to 1.49) −0.58 (−1.87 to 0.72) 0.38
Waist circumference (cm) −0.80 (−1.90 to 0.30) 0.71 (−0.39 to 1.81) −1.51 (−3.07 to 0.05) 0.056
Waist–hip ratio −3.03 (−4.72 to 1.35) −1.81 (−3.50 to −0.13) −1.22 (−3.60 to 1.16) 0.31
Body mass index (kg/m2) 0.02 (−0.30 to 0.32) 0.16 (−0.17 to 0.49) −0.14 (−0.60 to 0.28) 0.46
Blood pressure (mm Hg)
  Systolic −3.06 (−5.98 to −0.14) −1.57 (−4.49 to 1.34) −1.49 (−5.61 to 2.64) 0.47
  Diastolic −0.85 (−2.38 to 0.69) −0.08 (−1.62 to 1.45) −0.77 (−2.94 to 1.40) 0.49
Lipids (mmol/L)
  Cholesterol −0.24 (−0.33 to −0.14) 0.13 (0.04 to 0.23) −0.37 (−0.50 to −0.24) <0.0001
  HDL 0.06 (0.00 to 0.12) 0.00 (−0.06 to 0.05) 0.07 (−0.01 to 0.14) 0.10
  LDL −0.07 (−0.18 to 0.04) −0.03 (−0.13 to 0.08) −0.04 (−0.20 to 0.11) 0.61
  Triglyceride 0.06 (−0.06 to 0.18) 0.06 (−0.06 to 0.17) 0.00 (−0.16 to 0.17) 0.97
  HbA1c (mmol/mol) −0.05 (−0.22 to 0.12) 0.10 (−0.07 to 0.27) −0.15 (−0.40 to 0.09) 0.22
HbA1c, haemoglobin A1c; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.
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(2%) dropped out at end of intervention, which underlines the 
acceptability of the individually tailored intervention allowing 
them to set achievable goals for change in everyday activities.
In conclusion, a randomised, observer-blinded 16-week indi-
vidually tailored, theory-based behavioural intervention with 
motivational counselling and SMS reminders reduced daily 
sitting time by an average of 2 hours, improved general self-effi-
cacy, QoL, physical function, total cholesterol and reduced levels 
of pain and fatigue in sedentary patients with RA.
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